Evenity (Romosozumab) and NSAIDs (Ibuprofen, Naproxen): What Patients and Prescribers Need to Know

Is There a Direct Drug-Drug Interaction Between Romosozumab and NSAIDs?

There is no pharmacokinetic drug-drug interaction between romosozumab and NSAIDs. Romosozumab is a humanized monoclonal antibody eliminated through proteolytic catabolism, not through CYP450 enzymes or P-glycoprotein transporters. NSAIDs are metabolized primarily via CYP2C9, so no shared metabolic pathway exists between these two agents [1].

The FDA-approved prescribing information for romosozumab lists no NSAID-specific pharmacokinetic interaction [2]. What does exist is a pharmacodynamic concern: both drug classes can worsen cardiovascular outcomes, renal perfusion, and gastrointestinal integrity through separate but additive mechanisms. That overlap is the clinical issue.

Why Pharmacodynamic Interactions Matter Here

A pharmacodynamic interaction does not require shared metabolism. It occurs when two drugs produce overlapping physiological effects. In this case, romosozumab's boxed warning for major adverse cardiovascular events (MACE) combined with the well-established NSAID-associated cardiovascular risk creates an additive hazard profile that requires deliberate clinical management [2][3].

Romosozumab's Pharmacological Profile

Romosozumab is a sclerostin inhibitor. Sclerostin is a glycoprotein secreted by osteocytes that inhibits Wnt signaling and suppresses bone formation. By binding and neutralizing sclerostin, romosozumab activates osteoblast activity while also reducing osteoclast-driven bone resorption. The result is a dual anabolic and anti-resorptive effect not seen with bisphosphonates or denosumab [4].

The FRAME trial (N=7,180) demonstrated that romosozumab 210 mg monthly for 12 months reduced new vertebral fractures by 73% compared with placebo (P<0.001) [5]. The ARCH trial (N=4,093) compared romosozumab followed by alendronate versus alendronate alone and found a 48% reduction in new vertebral fractures and a 27% reduction in clinical fractures at 24 months [6]. Both trials confirmed the drug's efficacy. ARCH also surfaced the cardiovascular signal that led to the boxed warning.

The Cardiovascular Risk Signal: Romosozumab's Boxed Warning Explained

The FDA issued a boxed warning for romosozumab after the ARCH trial showed a higher rate of serious cardiovascular events in the romosozumab arm versus the alendronate arm: 2.5% versus 1.9%, a difference driven primarily by MI and stroke [6][2]. The absolute numbers were small but statistically notable given the 12-month exposure window.

The mechanism is not fully understood. Sclerostin may have a protective role in vascular calcification pathways, and blocking it could modulate vascular smooth muscle behavior [7]. A 2019 analysis published in the European Heart Journal found that genetic variants associated with lower sclerostin activity correlated with greater bone mineral density but also with higher risk of cardiovascular events, supporting biological plausibility for the ARCH finding [7].

Who Should Not Receive Romosozumab

The FDA label states that romosozumab should not be initiated in patients who have had a MI or stroke within the preceding 12 months [2]. Prescribers are instructed to weigh benefit versus risk in patients with other cardiovascular risk factors.

Where NSAIDs Compound the Problem

NSAIDs inhibit cyclooxygenase-1 (COX-1) and COX-2 enzymes. COX-2 inhibition reduces prostacyclin (PGI2) synthesis in vascular endothelium while preserving thromboxane A2 activity in platelets. This imbalance shifts the thrombotic-fibrinolytic equilibrium toward increased platelet aggregation and vasoconstriction [3].

A 2017 meta-analysis in BMJ (130,000 patient-years of data) found that all NSAIDs, including naproxen, were associated with an elevated risk of acute MI. Ibuprofen at doses above 1,200 mg/day and diclofenac showed the highest relative risk increases [8]. Naproxen showed the smallest cardiovascular signal among the common NSAIDs, which is why some guidelines conditionally prefer it when NSAID therapy is unavoidable in patients with moderate cardiovascular risk [9].

The 2015 FDA NSAID label update required all systemic NSAIDs to carry strengthened warnings about increased cardiovascular thrombotic events, heart failure, and stroke, with risk potentially elevated as early as the first weeks of use [3].

Gastrointestinal Risk: An Underappreciated Overlap

The GI risk of NSAIDs is well-established. COX-1 inhibition reduces prostaglandin E2 synthesis in gastric mucosa, impairing the protective mucus layer and increasing ulceration risk [10]. A Cochrane review of NSAID upper GI complications estimated that non-selective NSAIDs increased the risk of serious upper GI events by approximately 3.8-fold compared with non-use [10].

Romosozumab itself does not carry a specific GI warning. However, patients prescribed romosozumab are predominantly postmenopausal women over 65, a demographic that already carries elevated baseline GI bleeding risk [11]. Adding chronic NSAID use to this population compresses the safety margin considerably.

Proton Pump Inhibitors and Co-Prescribing Practice

The American College of Gastroenterology recommends co-prescribing a proton pump inhibitor (PPI) when NSAIDs are used in patients aged 65 or older, or in those with a prior GI event [11]. For a patient on romosozumab who also requires NSAID therapy, PPI co-prescribing is a practical risk-mitigation step, though it does not eliminate cardiovascular risk.

Topical NSAIDs as an Alternative

Topical diclofenac (1% gel or 1.5% solution) delivers meaningful local anti-inflammatory effect with substantially lower systemic absorption than oral NSAIDs. A 2017 Cochrane review of topical NSAIDs for chronic musculoskeletal pain found efficacy comparable to oral forms for knee osteoarthritis with significantly fewer GI adverse events [12]. For a patient on romosozumab who needs pain relief for a peripheral joint, topical diclofenac is a clinically defensible first step.

Renal Risk: COX-2, Prostaglandins, and Perfusion

NSAIDs reduce renal prostaglandin synthesis, which impairs afferent arteriolar dilation in the kidney. In patients who are volume-depleted, older, or have pre-existing chronic kidney disease (CKD), this effect can precipitate acute kidney injury (AKI) [13]. Denosumab, a drug commonly used after romosozumab in sequential therapy, requires dose adjustment for CKD. Preserving renal function during the romosozumab treatment window is therefore especially relevant for long-term skeletal management planning.

The FDA recommends monitoring renal function in patients initiating NSAID therapy who have pre-existing renal impairment, heart failure, or hepatic disease [3]. For patients on romosozumab, a baseline serum creatinine (SCr) and estimated glomerular filtration rate (eGFR) before initiating any NSAID course is reasonable clinical practice.

Specific NSAID Renal Risk Comparison

Among common NSAIDs, indomethacin carries the highest renal risk. Ibuprofen and naproxen carry intermediate risk. Sulindac has historically been considered renally sparing, though evidence is mixed [13]. If short-course NSAID therapy is unavoidable in a patient on romosozumab with borderline eGFR (60-90 mL/min/1.73m²), naproxen at the lowest effective dose for the shortest duration (fewer than 5 days where possible) is a more defensible choice than ibuprofen at full over-the-counter doses.

Blood Pressure Effects and Monitoring

NSAIDs can raise blood pressure by 3 to 5 mmHg on average in patients with existing hypertension, with some individuals experiencing larger increases [14]. A 2022 analysis in the Journal of the American Heart Association found that ibuprofen and naproxen both produced statistically significant mean systolic BP increases in hypertensive adults compared with acetaminophen over a 4-week observation period [14]. Celecoxib showed a smaller mean BP increase than ibuprofen or naproxen in that same study.

Hypertension is itself a cardiovascular risk factor. In patients already carrying the elevated MACE risk associated with romosozumab therapy, uncontrolled blood pressure raises the compound risk further. Blood pressure monitoring at each monthly romosozumab injection visit provides a straightforward surveillance opportunity.

Antihypertensive Drug Interactions With NSAIDs

NSAIDs blunt the effect of ACE inhibitors, ARBs, and diuretics through prostaglandin-dependent mechanisms [15]. A patient on lisinopril or losartan for hypertension who begins regular ibuprofen use may see measurable blood pressure increases, compounding the cardiovascular concern during romosozumab therapy. This triple interaction (romosozumab plus NSAID plus antihypertensive blunting) should prompt a medication review before initiating NSAIDs in any affected patient [15].

Practical Prescribing: A Decision Framework for Co-Use

The following decision framework applies to postmenopausal women on romosozumab 210 mg monthly who require analgesic therapy:

Step 1. Assess pain etiology. Determine whether pain is musculoskeletal, neuropathic, or procedural. NSAIDs are most effective for inflammatory musculoskeletal pain.

Step 2. Try acetaminophen first. Acetaminophen 500 to 1,000 mg every 6 to 8 hours (maximum 3,000 mg/day in older adults) has no cardiovascular or renal interaction with romosozumab and is the preferred first-line analgesic during the 12-month Evenity treatment course [16].

Step 3. Consider topical NSAID before oral. For localized joint pain (knee, hand), topical diclofenac 1% gel four times daily provides local anti-inflammatory benefit with systemic exposure approximately 6% that of oral diclofenac [12].

Step 4. If oral NSAID is required, stratify risk. Before prescribing any oral NSAID:

• Review cardiovascular history. If MI or stroke within 12 months, romosozumab is already contraindicated [2].
• Check baseline BP, SCr, and eGFR.
• Review antihypertensive regimen.
• Confirm no active GI ulceration or recent GI bleeding.

Step 5. Choose the lowest-risk NSAID at the lowest effective dose. Naproxen 220 to 440 mg twice daily (over-the-counter dosing) carries a smaller cardiovascular signal than ibuprofen at full therapeutic doses [8][9]. Limit duration to 5 days or fewer where clinically feasible.

Step 6. Add gastroprotection. Co-prescribe omeprazole 20 mg daily or equivalent PPI for any patient aged 65 or older using an oral NSAID concurrently with romosozumab [11].

Step 7. Monitor. Recheck BP at each monthly Evenity injection. Repeat SCr at 1 to 2 weeks if NSAID use continues beyond 5 days in a patient with eGFR below 60 mL/min/1.73m².

Patient Counseling Points

Patients self-managing pain with over-the-counter ibuprofen or naproxen while on romosozumab may not consider these drugs relevant to disclose during medication reviews. Clear, specific counseling is necessary.

Key points to communicate:

• Romosozumab increases the risk of heart attack and stroke, and so do NSAIDs when used regularly. Using both at the same time adds those risks together.
• Ibuprofen (Advil, Motrin) and naproxen (Aleve) sold over the counter are the same compounds used in prescription NSAIDs. The OTC labeling does not address the Evenity interaction.
• Acetaminophen (Tylenol) is the preferred pain reliever during the 12-month Evenity treatment course for most patients without liver disease.
• Patients should inform their prescriber before starting any NSAID, including OTC doses, while on Evenity.
• If chest pain, shortness of breath, sudden weakness, or facial drooping occurs during Evenity treatment, call 911 immediately. Do not attribute these symptoms to NSAID use without evaluation [2].

The Osteoporosis Foundation notes that adherence to the 12-injection romosozumab course is important for full skeletal benefit and that switching analgesics for the duration of treatment is a manageable trade-off for most patients [17].

Sequential Therapy Context: Why the 12-Month Window Matters

Romosozumab treatment is limited to 12 monthly injections. After the course ends, guidelines recommend transitioning to an anti-resorptive agent (alendronate or denosumab) to preserve the bone density gains [6][17]. The cardiovascular risk associated with romosozumab is confined to this 12-month window.

That finite duration changes the risk calculus. A patient with mild, intermittent musculoskeletal pain who can substitute acetaminophen or topical diclofenac for 12 months avoids a meaningful cardiovascular and renal risk period without permanently abandoning NSAID access. Framing the request as a time-limited analgesic substitution improves patient acceptance in clinical experience.

After completing romosozumab and transitioning to alendronate, the standard NSAID interaction profile returns to alendronate-specific considerations (primarily ensuring the patient takes alendronate on an empty stomach and remains upright, as NSAIDs do not affect alendronate's pharmacokinetics directly).

Special Populations: Elevated Baseline Risk

Patients over 75, those with established coronary artery disease, prior stroke, heart failure (NYHA class II or higher), eGFR below 45 mL/min/1.73m², or active peptic ulcer disease represent populations in whom oral NSAID co-use with romosozumab is very difficult to justify [2][3][13].

For these patients, the analgesic options include acetaminophen, topical diclofenac, low-dose tramadol (with appropriate prescribing caution), duloxetine for neuropathic or widespread musculoskeletal pain, or short-course physical therapy for mechanical pain. Each of these carries its own risk profile, but none adds to the MACE or renal risk burden during the romosozumab treatment window.

A 2021 review in Drugs and Aging found that acetaminophen remains the safest first-line analgesic for older adults with cardiovascular comorbidities across multiple guidelines, though liver safety requires attention at doses above 3,000 mg/day in this population [16].